Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 3
2016 1
2017 7
2018 17
2019 27
2020 28
2021 21
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 34697178

96 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H, Langer CJ, Paz-Ares L, Rodríguez-Abreu D, Halmos B, Garassino MC, Houghton B, Kurata T, Cheng Y, Lin J, Pietanza MC, Piperdi B, Gadgeel SM. Borghaei H, et al. Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11. Cancer. 2020. PMID: 32914866 Free PMC article.
Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
Hulsbergen AFC, Mammi M, Nagtegaal SHJ, Lak AM, Kavouridis V, Smith TR, Iorgulescu JB, Mekary RA, Verhoeff JJC, Broekman MLD, Phillips JG. Hulsbergen AFC, et al. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):258-267. doi: 10.1016/j.ijrobp.2020.04.018. Epub 2020 Apr 23. Int J Radiat Oncol Biol Phys. 2020. PMID: 32335185
Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer.
Nakashima K, Hata K, Hotta T, Tanaka S, Mitarai Y, Okuno T, Tanino A, Nakao M, Amano Y, Hamaguchi M, Okimoto T, Hamaguchi S, Nagao T, Kurimoto N, Isobe T, Tsubata Y. Nakashima K, et al. J Med Invest. 2021;68(3.4):260-264. doi: 10.2152/jmi.68.260. J Med Invest. 2021. PMID: 34759141 Free article.
96 results